Ark hopes Cerepro will drive sales in 2009
This article was originally published in Scrip
Executive Summary
Ark Therapeutics's Cerepro (stimagene ceradenovec) is likely to have a significant impact on the company's 2009 sales if physicians from more countries decide to apply for it on a named-patient basis.